CoChat

Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1

Parkes, David G, Mace, Kenneth F, Trautmann, Michael E · 2013 · Expert Opinion on Drug Discovery
Cited by 108

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: The GLP-1 receptor agonist exenatide is synthetic exendin-4, a peptide originally isolated from the salivary secretions of the Gila monster. Exenatide was developed as a first-in-class diabetes therapy, with immediate- and extended-release formulations. In preclinical diabetes models, exenatide enhanced glucose-dependent insulin secretion, suppressed inappropriately elevated glucagon secretion, slowed gastric emptying, reduced body weight, enhanced satiety, and preserved pancreatic β-cell function. In clinical trials, both exenatide formulations reduced hyperglycemia in patients with type 2 diabetes mellitus (T2DM) and were associated with weight loss. AREAS COVERED: This article reviews the development of exenatide from its discovery and preclinical investigations, to the elucidation of its pharmacological mechanisms of action in mammalian systems. The article also presents the pharmacokinetic profiling and toxicology studies of exenatide, as well as its validation in clinical trials. EXPERT OPINION: GLP-1 receptor agonists represent a new paradigm for the treatment of patients with T2DM. By leveraging incretin physiology, a natural regulatory system that coordinates oral nutrient intake with mechanisms of metabolic control, these agents address multiple core defects in the pathophysiology of T2DM. Studies have identified unique benefits including improvements in glycemic control and weight, and the potential for beneficial effects on the cardiometabolic system without the increased risk of hypoglycemia associated with insulin therapy. Peptide hormone therapeutics can offer significant advantages over small molecule drug targets when it comes to specificity, potency, and more predictable side effects. As exemplified by exenatide, injectable peptides can be important drugs for the treatment of chronic diseases, such as T2DM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1517/17460441.2013.741580

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Research works printed but not linked: 101

  1. 10.1161/ATVBAHA.107.147538 · DOI · Paper page
  2. Göke R, 1993, Biol Chem, 268, 19650, 10.1016/S0021-9258(19)36565-2 · DOI · Paper page
  3. 10.1159/000194739 · DOI
  4. 10.2337/diacare.19.6.580 · DOI · Paper page
  5. 10.1016/j.mce.2008.08.012 · DOI · Paper page
  6. 10.1007/s001250050613 · DOI · Paper page
  7. Nauck MA, 1997, Am J Physiol, 273, E981
  8. 10.1055/s-2004-826161 · DOI
  9. 10.3109/9780203217412-17 · DOI
  10. Edvell A, 1999, Endocrin, 140, 778, 10.1210/endo.140.2.6514 · doi:10.1210/endo.140.2.6514 · Paper page
  11. 10.2337/diabetes.49.5.741 · DOI · Paper page
  12. 10.1146/annurev.med.57.110104.115624 · DOI · Paper page
  13. 10.1172/JCI119482 · DOI · Paper page
  14. 10.2337/diab.44.9.1126 · DOI · Paper page
  15. 10.1210/en.136.8.3585 · DOI · Paper page
  16. Raufman JP, 1992, J Biol Chem, 267, 21432, 10.1016/S0021-9258(19)36628-1 · DOI · Paper page
  17. 10.3109/10606820213687 · doi:10.3109/10606820213687 · Paper page
  18. 10.1016/j.regpep.2003.10.028 · DOI · Paper page
  19. 10.1210/endo.137.7.8770921 · DOI · Paper page
  20. Meloni AR, 2012, Diab Obes Metab
  21. 10.2337/diabetes.47.4.646 · DOI · Paper page
  22. 10.2337/diabetes.47.7.1046 · DOI · Paper page
  23. 10.2337/diabetes.47.4.632 · DOI · Paper page
  24. 10.2337/diabetes.48.10.1979 · DOI · Paper page
  25. 10.2337/diabetes.50.8.1720 · DOI · Paper page
  26. 10.2337/diabetes.52.2.365 · DOI · Paper page
  27. 10.3949/ccjm.76.s5.03 · DOI · Paper page
  28. 10.1074/jbc.272.7.4108 · DOI · Paper page
  29. 10.2337/diab.42.11.1678 · DOI · Paper page
  30. 10.1016/0167-0115(96)00135-8 · DOI
  31. 10.1016/0196-9781(94)90204-6 · DOI
  32. 10.1016/0922-4106(94)90085-X · DOI
  33. 10.1002/(SICI)1097-4652(199709)172:3<275::AID-JCP1>3.0.CO;2-L · DOI · Paper page
  34. 10.1016/S0165-1838(99)00086-7 · DOI
  35. Yang H, 1998, Am J Physiol, 273, C675, 10.1152/ajpcell.1998.275.3.C675 · DOI · Paper page
  36. 10.2337/diabetes.48.5.1026 · DOI · Paper page
  37. 10.1210/endo.141.6.7490 · doi:10.1210/endo.141.6.7490 · Paper page
  38. 10.1053/meta.2001.22519 · DOI · Paper page
  39. 10.1210/jcem.87.3.8337 · doi:10.1210/jcem.87.3.8337 · Paper page
  40. 10.1007/s001250051111 · DOI · Paper page
  41. Gedulin B, 1999, Diabetes, 48, A199
  42. 10.2337/diacare.24.2.371 · DOI · Paper page
  43. 10.1038/sj.ijo.0803284 · DOI
  44. 10.2337/diabetes.48.12.2270 · DOI · Paper page
  45. 10.2337/diabetes.50.7.1562 · DOI · Paper page
  46. 10.2337/diabetes.51.5.1443 · DOI · Paper page
  47. 10.1210/en.2004-1349 · DOI · Paper page
  48. 10.1002/ddr.1195 · DOI · Paper page
  49. Eng J, 1996, Diabetes, 45, 152A
  50. 10.1530/eje.0.1500097 · DOI · Paper page
  51. Parkes D, 2001, Diabetes, 50, A313
  52. 10.2337/diabetes.52.3.734 · DOI · Paper page
  53. 10.1152/ajpendo.00030.2002 · DOI · Paper page
  54. 10.1007/s00125-002-0828-3 · DOI · Paper page
  55. Jodka C, 1998, Diabetes, 47, A403
  56. Kinzig KP, 2002, J Neurosci, 22, 10470, 10.1523/JNEUROSCI.22-23-10470.2002 · DOI · Paper page
  57. Egan JM, 1994, Endocrinology, 135, 2070, 10.1210/endo.135.5.7956929 · doi:10.1210/endo.135.5.7956929 · Paper page
  58. 10.1677/jme.0.0190241 · DOI · Paper page
  59. 10.1089/met.2008.0095 · DOI · Paper page
  60. 10.1016/j.bbrc.2009.01.003 · DOI · Paper page
  61. 10.1186/1475-2840-9-32 · DOI · Paper page
  62. 10.1016/j.jacc.2008.10.033 · DOI · Paper page
  63. 10.1186/1475-2840-9-76 · DOI · Paper page
  64. 10.1007/s00125-009-1611-5 · DOI · Paper page
  65. 10.1111/j.1476-5381.2009.00486.x · DOI · Paper page
  66. 10.1124/jpet.300.3.958 · DOI · Paper page
  67. 10.1016/j.expneurol.2006.09.028 · DOI · Paper page
  68. 10.1371/journal.pone.0032008 · DOI · Paper page
  69. 10.2174/138920006776873490 · DOI · Paper page
  70. 10.1124/dmd.111.042291 · DOI
  71. 10.1152/ajpendo.00479.2010 · DOI · Paper page
  72. 10.2337/db09-0626 · DOI · Paper page
  73. Tatarkiewicz K, 2011, Diabetologia, 54, 185
  74. Bhavsar S, 2012, Curr Diab Rev
  75. 10.1016/j.clinthera.2012.04.013 · DOI · Paper page
  76. MacConell L, 2012, Diabetes Metab Syndr Obes, 5, 29
  77. MacConell L, 2012, Diabetes, 61, A598
  78. 10.3810/pgm.2010.05.2149 · DOI · Paper page
  79. 10.1089/dia.2011.0050 · DOI · Paper page
  80. 10.2337/dc10-0482 · DOI · Paper page
  81. 10.1111/j.1464-5491.2012.03652.x · DOI · Paper page
  82. 10.1111/j.1365-2125.2007.02890.x · DOI · Paper page
  83. 10.1038/ajh.2009.245 · DOI · Paper page
  84. 10.1093/eurheartj/ehr309 · DOI · Paper page
  85. 10.1161/CIRCINTERVENTIONS.112.968388 · DOI · Paper page
  86. 10.1210/jc.2011-3456 · DOI · Paper page
  87. 10.1007/s00125-011-2440-x · DOI
  88. 10.1210/jc.2003-032001 · DOI · Paper page
  89. 10.1530/EJE-11-0330 · DOI · Paper page
  90. 10.2337/dc11-0096 · DOI · Paper page
  91. Buse JB, 2012, Lancet
  92. 10.1111/j.1463-1326.2011.01533.x · DOI
  93. 10.1345/aph.1M676 · DOI · Paper page
  94. 10.1185/03007990902820519 · DOI · Paper page
  95. 10.1111/j.1463-1326.2011.01376.x · DOI · Paper page
  96. Raufman JP, 1982, Am J Physiol, 242, G470
  97. 10.1046/j.1471-4159.1996.67051982.x · DOI · Paper page
  98. 10.1053/meta.2000.6251 · DOI
  99. 10.1055/s-2002-29087 · DOI · Paper page
  100. 10.1007/s00125-005-1795-2 · DOI
  101. 10.1016/j.ijpharm.2008.01.015 · DOI

Cited by

See all 108

Metadata

Authors
Parkes, D. G., Mace, K. F., & Trautmann, M. E.
Venue
Expert Opinion on Drug Discovery
Published
2012-12-12
Volume
8
Issue
2
Pages
219-244
ISSN
  • 1746-0441 (ISSN-L)
  • 1746-045X
OpenAlex
W2059228484
Cited by
108
References
30
FWCI
6.44
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. https://app.cochat.ai/papers/10.1517/17460441.2013.741580
The paper
Parkes, D. G., Mace, K. F., & Trautmann, M. E. (2013). Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. Expert Opinion on Drug Discovery. https://doi.org/10.1517/17460441.2013.741580

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.